Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 74 clinical trials
Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

or chronic myelomonocytic leukemia who have not received prior treatment (treatment-naive). Chemotherapy drugs, such as venetoclax, cedazuridine, and decitabine, work in different ways to stop the

decitabine
hydroxyurea
cancer
myelomonocytic leukemia
chronic myelomonocytic leukemia
  • 0 views
  • 04 Oct, 2022
  • 1 location
A Phase 2 Study of the MEK Inhibitor Trametinib (NSC# 763093) in Children With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

This phase II trial studies how well trametinib works in treating patients with juvenile myelomonocytic leukemia that has come back (relapsed) or does not respond to treatment (refractory

bcr/abl
total serum bilirubin
biologic agent
monoclonal antibodies
cytarabine
  • 254 views
  • 27 Oct, 2022
  • 39 locations
Phase I/II Study of SP-2577 (Seclidemstat) in Combination With Azacitidine for Patients With Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

This phase I/II trial identifies the best dose of seclidemstat when given together with azacitidine in treating patients with myelodysplastic syndrome or chronic myelomonocytic leukemia

TP53
granulocyte colony stimulating factor
filgrastim
cancer
leukemia
  • 0 views
  • 17 Oct, 2022
  • 1 location
Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML

Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML).

flt3 internal tandem duplication
hydroxyurea
induction chemotherapy
tyrosine
refractory acute myeloid leukemia (aml)
  • 6 views
  • 03 Feb, 2022
  • 4 locations
Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MF and CMML (HSCT 002)

In this study, tagraxofusp (Tag) is given to patients with CD 123+ myelofibrosis (MF), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) after allogeneic stem cell

chronic myelomonocytic leukemia
cancer
  • 0 views
  • 04 Oct, 2022
  • 1 location
Inqovi Maintenance Therapy in Myeloid Neoplasms

This research is being done to see if the drug Inqov is effective in reducing the chance of myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) relapsing after standard of

cell transplantation
antifungal agents
leukemia
decitabine
graft versus host disease
  • 0 views
  • 17 Oct, 2021
  • 1 location
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

positive acute myeloid leukemia, chronic myelomonocytic leukemia, or high-risk myelodysplastic syndrome/myeloproliferative neoplasm that has come back (recurrent) or has not responded to treatment

  • 17 views
  • 21 Feb, 2022
  • 1 location
A Study of E7820 in People With Bone Marrow (Myeloid) Cancers

will have acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML).

direct bilirubin
lenalidomide
induction chemotherapy
leukemia
myelodysplastic syndromes
  • 0 views
  • 07 Oct, 2022
  • 7 locations
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

This phase II trial studies the effect of venetoclax together with busulfan, cladribine, and fludarabine in treating patients with high-risk acute myeloid leukemia or myelodysplastic syndrome who are undergoing stem cell transplant. Chemotherapy drugs, such as venetoclax, busulfan, cladribine, and fludarabine, work in different ways to stop the growth of …

KRAS
cell transplantation
residual tumor
cancer
gilbert's syndrome
  • 0 views
  • 28 Oct, 2022
  • 1 location
A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies (BEXMAB)

This is a study to assess the safety of increasing dose levels of bexmarilimab when combined with standard of care (SoC) in patients with myelodysplastic syndrome (MDS) or chronic myelomonocytic

myeloid leukemia
myelomonocytic leukemia
azacitidine
venetoclax
leukemia
  • 0 views
  • 04 Oct, 2022
  • 4 locations